Nafamostat Mesilate
(rINNM)
Synonyms: FUT-175; Mesilato de nafamostat; Nafamostat, Mésilate de; Nafamostat Mesylate naphthyl p-guanidinobenzoate dimethanesulfonate.
Cyrillic synonym: Нафамостата Мезилат.
Chemical information
Chemical formula: C21H25N5O8S2 = 539.6.
CAS — 81525-10-2 (nafamostat); 82956-11-4 (nafamostat mesilate).
Profile
Like aprotinin nafamostat is a proteolytic enzyme inhibitor. The mesilate is used in the treatment of acute pancreatitis and disseminated intravascular coagulation, and as an anticoagulant in haemodialysis. Hyperkalaemia has been reported.
◊ References.
1. Yanamoto H, et al. Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 1992; 30: 358–63
2. Akizawa T, et al. Nafamostat mesilate: a regional anticoagulant for haemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376–81
3. Miyata T, et al. Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet 1993; 341: 1353
4. Murase M, et al. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993; 88: 432–6
5. Kitagawa H, et al. Hyperkalaemia due to nafamostat mesylate. N Engl J Med 1995; 332: 687
6. Yamazato M, et al. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient. Intern Med 2002; 41: 864–6
7. Kaminishi Y, et al. Effects of nafamostat mesilate and minimaldose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 644–50
8. Ota T, et al. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interact Cardiovasc Thorac Surg 2007; 6: 270–3.
2. Akizawa T, et al. Nafamostat mesilate: a regional anticoagulant for haemodialysis in patients at high risk for bleeding. Nephron 1993; 64: 376–81
3. Miyata T, et al. Effectiveness of nafamostat mesilate on glomerulonephritis in immune-complex diseases. Lancet 1993; 341: 1353
4. Murase M, et al. Nafamostat mesilate reduces blood loss during open heart surgery. Circulation 1993; 88: 432–6
5. Kitagawa H, et al. Hyperkalaemia due to nafamostat mesylate. N Engl J Med 1995; 332: 687
6. Yamazato M, et al. Severe abdominal pain associated with allergic reaction to nafamostat mesilate in a chronic hemodialysis patient. Intern Med 2002; 41: 864–6
7. Kaminishi Y, et al. Effects of nafamostat mesilate and minimaldose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. Ann Thorac Surg 2004; 77: 644–50
8. Ota T, et al. Cardiopulmonary bypass using nafamostat mesilate for patients with infective endocarditis and recent intracranial hemorrhage. Interact Cardiovasc Thorac Surg 2007; 6: 270–3.
Published May 08, 2019.